INV441 / invIOs - LARVOL DELTA

Enhancement Platform for immune Cells (EPiC): invIOs's innovative cell-therapy platform for creating personalized cancer treatments (ESMO-TAT 2023) - "APN401 is an autologous cell therapy comprising peripheral blood mononuclear cells (PBMCs), while INV441 utilizes tumor infiltrating lymphocytes (TILs). The advantage of using an RNAi-based technology is that it allows transient and highly specific modification of immune cells. Beyond silencing, EPiC enables over-expression of proteins and combinations of modalities (e.g. mRNA) to modify multiple immune pathways and create the next generation of personalized immune cell therapies."

Immune cell • IO biomarker • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • UBR5